The latter was unexpected considering that the Chk2-p53 pathway is well established and both TP53 and CHEK2 were identified in our screen and may suggest a role of residual non-catalytic functions of Chk2 in the leukemia cells’ response to CLM-induced cytotoxicity. The gene discussed is TP53; the disease is leukemia.